ArticleAcademia oncology2025
Serous tubal intraepithelial carcinoma-looking into the earliest events of ovarian cancer development.
Article in Academia oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Models of high-grade serous carcinoma of tubo-ovarian origin.Oncology reviews · 2026Review
- Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancer.medRxiv : the preprint server for health sciences · 2025Article
- Integrated Spatial Analysis of Ovarian Precancerous Lesions.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Among human malignancies, ovarian epithelial neoplasms are unique because they are unlikely to develop from their cognate organs, the ovaries (specifically, the surface mesothelium). The updated paradigm about the origin of high-grade serous carcinoma (HGSC) suggests that many HGSCs derive from the fallopian tubes following a sequential tumor progression, from pathologically defined p53 signature, serous tubal intraepithelial lesion, and serous tubal intraepithelial carcinoma (STIC) to HGSC that later spreads to ovarian tissues and disseminates. Despite the fact that the biological and clinical significance of each of those precursor lesions is yet to be elucidated, molecular and morphological correlative studies demonstrate unique features associated with various precancerous lesions. Chromosomal instability, aneuploidy patterns, and the activation of specific cancer signaling pathways attribute tumor progression to HGSC. The knowledge gained thus far is transforming various aspects of ovarian cancer research and gynecological practice. Opportunistic salpingectomy prevents HGSC in average-risk women, and molecular analyses in routine liquid-based cervical Pap tests hold promise to detect STIC- and HGSC-related tissue biomarkers. This review article will summarize those key findings in the earliest development of HGSC precursors and discuss the future challenges and promises of translating this paradigm shift to leverage standardization in diagnostic, early detection, and prevention of this devastating ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.